Showing results (211-220 of 235) with videos related to
Sort By:
Pageof 24
Blood|January 29, 2021
Modeling and targeting of erythroleukemia by hematopoietic genome editingIlaria Iacobucci, Chunxu Qu, Elena Varotto, et al.Journal for Immunotherapy of Cancer|October 8, 2024
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myelomaJan H Frenking, Xiang Zhou, Vivien Wagner, et al.Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.Blood|May 5, 2022
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasmsAdam S Sperling, Veronica A Guerra, James A Kennedy, et al.Journal of Medical Virology|March 27, 2026
Association of Viraemic Phase Viral Load, Antibody Responses, and Immune Biomarkers With Severe DengueKalichamy Alagarasu, Yogesh K Gurav, Anisha Pulinchani, et al.Journal for Immunotherapy of Cancer|February 18, 2026
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2RαHeydar Moravej, Taha Rakhshandehroo, Radia M M Khan, et al.Molecular Cell|August 22, 2025
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradationMikołaj Słabicki, Jiho Park, Radosław P Nowak, et al.Haematologica|May 28, 2026
A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myelomaOmar Nadeem, Robert A Redd, Peter M Barth, et al.Pageof 24